Myriad Genetics (MYGN) Return on Capital Employed (2011 - 2026)

Myriad Genetics has disclosed Return on Capital Employed across 16 years of filings, most recently posting 69.45% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 5507.0% year-over-year to 69.45%; the TTM figure through Mar 2026 stood at 69.45% (down 5507.0% YoY), while the FY2025 annual figure was 52.8%, down 3942.0% from the prior year.
• Return on Capital Employed slipped to 69.45% in Q1 2026, from 66.35% in the prior quarter.
• Over the last five years, Return on Capital Employed for MYGN reached as high as 12.15% in Q3 2022 and fell as low as 75.81% in Q3 2025.
• The 5-year median for Return on Capital Employed is 16.43% (2024), against an average of 30.08%.
• Annual changes were most pronounced in 2024 — Return on Capital Employed soared 1655 bps — and 2025, when it tumbled 6334 bps.
• A 5-year view of Return on Capital Employed shows it stood at 13.16% in 2022, then tumbled by 97 bps to 25.95% in 2023, then jumped by 47 bps to 13.86% in 2024, then plunged by 379 bps to 66.35% in 2025, then slipped by 5 bps to 69.45% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 69.45%, 66.35%, and 75.81% for Q1 2026, Q4 2025, and Q3 2025 respectively.